{"id":"autologous-serum-20","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Infection risk (from preparation/handling)"},{"rate":null,"effect":"Allergic reaction"}]},"_chembl":{"chemblId":"CHEMBL2109149","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The preparation is derived from the patient's own serum and contains naturally occurring growth factors (EGF, FGF, TGF-β), immunoglobulins, and other bioactive proteins that support epithelial cell proliferation and migration. When applied topically to the ocular surface, these components enhance corneal wound healing, reduce inflammation, and improve tear film stability in patients with severe dry eye or corneal epithelial defects.","oneSentence":"Autologous serum 20% is a topical ophthalmic preparation of the patient's own blood serum that provides growth factors and immunomodulatory components to promote corneal healing and reduce ocular surface inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:59.898Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe dry eye syndrome"},{"name":"Corneal epithelial defects"},{"name":"Ocular surface disease"}]},"trialDetails":[{"nctId":"NCT06959771","phase":"PHASE1, PHASE2","title":"Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-16","conditions":"CD40L-HyperIgM Syndrome","enrollment":1},{"nctId":"NCT06839326","phase":"NA","title":"Efficacy of Autologous Conditioned Serum in Temporomandibular Joint Disorder","status":"COMPLETED","sponsor":"Batman University","startDate":"2024-11-01","conditions":"Temporomandibular Joint Osteoarthritis","enrollment":75},{"nctId":"NCT07469865","phase":"NA","title":"Efficacy and Safety of 20% and 100% Autologous Serum Eye Drops in Patients With Severe Dry Eye Disease (AST)","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2021-11-30","conditions":"Dry Eye Disease","enrollment":46},{"nctId":"NCT00716066","phase":"PHASE2","title":"Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2008-06","conditions":"Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune","enrollment":53},{"nctId":"NCT04196413","phase":"PHASE1","title":"GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2020-06-04","conditions":"Glioma of Spinal Cord, Glioma of Brainstem","enrollment":97},{"nctId":"NCT03233152","phase":"PHASE1, PHASE2","title":"A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2016-11-17","conditions":"Glioblastoma","enrollment":110},{"nctId":"NCT01526096","phase":"PHASE1","title":"Stem Cell Transplantation for Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2011-07-12","conditions":"Myeloma","enrollment":30},{"nctId":"NCT05371093","phase":"PHASE3","title":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2022-09-22","conditions":"Relapsed/Refractory Follicular Lymphoma","enrollment":231},{"nctId":"NCT04007029","phase":"PHASE1","title":"Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-10-04","conditions":"CD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia","enrollment":24},{"nctId":"NCT02681302","phase":"PHASE1, PHASE2","title":"Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2016-06-07","conditions":"Multiple Myeloma, Lymphoma","enrollment":46},{"nctId":"NCT07014059","phase":"PHASE2","title":"Autologous Serum Obtained by a Closed-Circuit Collection Device","status":"NOT_YET_RECRUITING","sponsor":"GIANCARLO FATOBENE","startDate":"2025-06-20","conditions":"GVHD, Meibomian Gland Dysfunction (Disorder), Stevens-Johnson Syndrome","enrollment":16},{"nctId":"NCT02953509","phase":"PHASE1, PHASE2","title":"Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2016-11-21","conditions":"Non Hodgkin Lymphoma","enrollment":178},{"nctId":"NCT06803758","phase":"NA","title":"Teicoplanin Allergy Testing Using Autologous Serum (TATAS)","status":"RECRUITING","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2025-01-08","conditions":"Drug Allergy","enrollment":20},{"nctId":"NCT02348216","phase":"PHASE1, PHASE2","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2015-04-21","conditions":"Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL)","enrollment":307},{"nctId":"NCT06294015","phase":"PHASE4","title":"Efficacy of 20% Autologous Serum Drops in the Treatment of Corneal Epitheliopathy Associated With Antihypertensive Glaucoma Drops.","status":"NOT_YET_RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2024-03","conditions":"Corneal Epitheliopathy, Glaucoma, Corneal Disease","enrollment":25},{"nctId":"NCT03286166","phase":"","title":"Single Center, Prospective, Randomized, Controlled, Non-significant Risk","status":"WITHDRAWN","sponsor":"Toyos Clinic","startDate":"2021-12-01","conditions":"Dry Eye","enrollment":""},{"nctId":"NCT04683796","phase":"PHASE3","title":"Comparison of Efficacy Between 100% Platelet-rich Plasma and 100% Serum Eye Drops in Dry Eye Disease","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2021-02-01","conditions":"Dry Eye Disease","enrollment":96},{"nctId":"NCT01035463","phase":"PHASE1, PHASE2","title":"Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2009-11-12","conditions":"Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma","enrollment":74},{"nctId":"NCT00572013","phase":"PHASE1, PHASE2","title":"Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"1998-05-12","conditions":"Lymphoma","enrollment":32},{"nctId":"NCT00007852","phase":"PHASE2","title":"Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2000-09-01","conditions":"Lymphoma","enrollment":44},{"nctId":"NCT03818737","phase":"PHASE3","title":"Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES)","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-03-28","conditions":"Osteoarthritis","enrollment":475},{"nctId":"NCT05944757","phase":"NA","title":"Compare of PRP Autologous Serum and Autologous Serum by Intrastromal Injection in Different Eye Disease Conditions","status":"UNKNOWN","sponsor":"Anita Syla Lokaj","startDate":"2021-09-01","conditions":"PRP","enrollment":40},{"nctId":"NCT02366728","phase":"PHASE2","title":"DC Migration Study for Newly-Diagnosed GBM","status":"COMPLETED","sponsor":"Mustafa Khasraw, MBChB, MD, FRCP, FRACP","startDate":"2015-10-12","conditions":"Glioblastoma, Astrocytoma, Grade IV, Giant Cell Glioblastoma","enrollment":64},{"nctId":"NCT04334174","phase":"PHASE2","title":"Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas","status":"WITHDRAWN","sponsor":"University of Kansas Medical Center","startDate":"2020-05-29","conditions":"T Cell Lymphoma","enrollment":""},{"nctId":"NCT00096460","phase":"PHASE2, PHASE3","title":"Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2004-08","conditions":"Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma","enrollment":30},{"nctId":"NCT04482413","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease","status":"UNKNOWN","sponsor":"Nature Cell Co. Ltd.","startDate":"2023-02-01","conditions":"Alzheimer Disease","enrollment":100},{"nctId":"NCT02706405","phase":"PHASE1","title":"JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2016-11-15","conditions":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma","enrollment":30},{"nctId":"NCT01514344","phase":"PHASE2","title":"Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma","status":"COMPLETED","sponsor":"Andres J. M. Ferreri","startDate":"2011-12","conditions":"Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma","enrollment":20},{"nctId":"NCT05331859","phase":"PHASE1","title":"Topical Insulin Versus Autologous Serum After Corneal Surgeries","status":"UNKNOWN","sponsor":"Benha University","startDate":"2022-05","conditions":"Corneal Epithelial Wound","enrollment":250},{"nctId":"NCT03021681","phase":"NA","title":"An Exploratory Study on the Treatment of Chronic Obstructive Pulmonary Disease With Autologous Bronchial Basal Cell Transplantation","status":"COMPLETED","sponsor":"Huai'an No.1 People's Hospital","startDate":"2016-11","conditions":"Cell Transplantation","enrollment":18},{"nctId":"NCT04971005","phase":"PHASE2","title":"Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial","status":"TERMINATED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2021-08-27","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":1},{"nctId":"NCT00238862","phase":"NA","title":"Treatment of PED With AMT and Autologous Serum","status":"COMPLETED","sponsor":"King Khaled Eye Specialist Hospital","startDate":"2005-10","conditions":"Corneal Epithelial Defect","enrollment":180},{"nctId":"NCT02059239","phase":"PHASE1, PHASE2","title":"Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2014-06-04","conditions":"Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma","enrollment":34},{"nctId":"NCT00469014","phase":"PHASE2","title":"Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-09","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia","enrollment":72},{"nctId":"NCT04505748","phase":"NA","title":"Is Self-transfusion Safe After Total Knee Arthroplasty in Terms of Nephrotoxicity of Gentamicin From Bone Cement?","status":"COMPLETED","sponsor":"University Hospital, Alexandroupolis","startDate":"2020-01-01","conditions":"Arthroplasty Complications, Total Knee Arthroplasty","enrollment":40},{"nctId":"NCT00005617","phase":"PHASE1","title":"Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"1997-07","conditions":"Melanoma","enrollment":""},{"nctId":"NCT03014804","phase":"PHASE2","title":"Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma","status":"WITHDRAWN","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-12-01","conditions":"Giant Cell Glioblastoma, Gliosarcoma, Oligodendroglioma","enrollment":""},{"nctId":"NCT00992446","phase":"PHASE2","title":"Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2010-09-02","conditions":"Adult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma","enrollment":27},{"nctId":"NCT03579927","phase":"PHASE1, PHASE2","title":"CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-03","conditions":"CD19 Positive, Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT00587990","phase":"PHASE1, PHASE2","title":"Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)","status":"TERMINATED","sponsor":"Joshua M Hare","startDate":"2007-11","conditions":"Stem Cell Transplantation, Ventricular Dysfunction, Left","enrollment":9},{"nctId":"NCT00266110","phase":"PHASE2","title":"Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2005-12","conditions":"Breast Cancer","enrollment":17},{"nctId":"NCT03436576","phase":"PHASE3","title":"Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2018-09-12","conditions":"Dry Eye, Keratoconjunctivitis Sicca, Sjogren's Syndrome","enrollment":20},{"nctId":"NCT02983097","phase":"PHASE1, PHASE2","title":"Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP","status":"TERMINATED","sponsor":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","startDate":"2010-11","conditions":"Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma Grade III (FL III°), Mantle Cell Lymphoma (MCL), Blastoid Variant","enrollment":34},{"nctId":"NCT01562977","phase":"PHASE2","title":"Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2011-04","conditions":"Aggressive Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma","enrollment":82},{"nctId":"NCT00088985","phase":"PHASE2","title":"Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer","status":"TERMINATED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2004-01","conditions":"Breast Cancer","enrollment":56},{"nctId":"NCT02194374","phase":"PHASE1","title":"Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-01","conditions":"Leukemia","enrollment":""},{"nctId":"NCT02961816","phase":"PHASE2","title":"Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-06","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT02060955","phase":"PHASE2","title":"Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan","status":"TERMINATED","sponsor":"CytoVac A/S","startDate":"2014-02","conditions":"Glioblastoma Multiforme","enrollment":25},{"nctId":"NCT02752763","phase":"PHASE4","title":"Comparison of Autologous Serum Versus Preservative Free Artificial Tear","status":"COMPLETED","sponsor":"Niğde State Hospital","startDate":"2015-10","conditions":"Dry Eye","enrollment":24},{"nctId":"NCT01421173","phase":"PHASE1","title":"Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-08","conditions":"Lymphoma","enrollment":78},{"nctId":"NCT00550498","phase":"PHASE1","title":"Stem Cell Transplantation in Ocular Lesions of Behcet's Disease","status":"TERMINATED","sponsor":"Tehran University of Medical Sciences","startDate":"2007-12","conditions":"Retinitis, Behcet's Syndrome","enrollment":5},{"nctId":"NCT02291731","phase":"NA","title":"Autologous Serum Eye Drops With Contact Lenses for Corneal Epithelial Defects","status":"COMPLETED","sponsor":"E-DA Hospital","startDate":"2014-09","conditions":"Corneal Diseases","enrollment":21},{"nctId":"NCT00790764","phase":"PHASE2","title":"Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)","status":"SUSPENDED","sponsor":"TCA Cellular Therapy","startDate":"2008-11","conditions":"Heart Disease, Blocked Arteries, Coronary Ischemia","enrollment":60},{"nctId":"NCT01120925","phase":"PHASE1, PHASE2","title":"Autologous Bone Marrow Derived Stem Cells in Decompensate Cirrhotic Patients","status":"COMPLETED","sponsor":"Royan Institute","startDate":"2010-05","conditions":"Liver Cirrhosis","enrollment":30},{"nctId":"NCT00787761","phase":"PHASE2","title":"Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer","status":"COMPLETED","sponsor":"Northside Hospital, Inc.","startDate":"2007-04","conditions":"Myeloproliferative Disorders, Kidney Cancer, Leukemia","enrollment":24},{"nctId":"NCT00550524","phase":"PHASE1","title":"Stem Cell Transplantation for the Treatment of Knee Osteoarthritis","status":"UNKNOWN","sponsor":"Tehran University of Medical Sciences","startDate":"2007-12","conditions":"Knee Osteoarthritis","enrollment":5},{"nctId":"NCT01075347","phase":"PHASE1","title":"Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2007-03","conditions":"Corneal Epithelial Defect, Diabetic Retinopathy, Penetrating Keratoplasty","enrollment":165},{"nctId":"NCT00557817","phase":"PHASE2, PHASE3","title":"Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)","status":"COMPLETED","sponsor":"University of Liege","startDate":"2004-03","conditions":"Hematological Malignancies","enrollment":125},{"nctId":"NCT00779987","phase":"PHASE2","title":"Autologous Serum Efficacy Study in Patients With Severe Dry Eye","status":"COMPLETED","sponsor":"University of Chile","startDate":"2008-10","conditions":"Dry Eye","enrollment":12},{"nctId":"NCT00385125","phase":"PHASE2","title":"Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL","status":"UNKNOWN","sponsor":"University of Magdeburg","startDate":"2004-08","conditions":"Lymphoma, High-Grade","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Autologus serum low concentration"],"phase":"phase_3","status":"active","brandName":"Autologous Serum 20%","genericName":"Autologous Serum 20%","companyName":"Pontificia Universidad Catolica de Chile","companyId":"pontificia-universidad-catolica-de-chile","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Autologous serum 20% is a topical ophthalmic preparation of the patient's own blood serum that provides growth factors and immunomodulatory components to promote corneal healing and reduce ocular surface inflammation. Used for Severe dry eye syndrome, Corneal epithelial defects, Ocular surface disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}